LiveSlider PreserVision AREDS2 Formula + Multivitamin The benefits of PreserVision AREDS2 Formula plus a daily multivitamin.*PreserVision AREDS 2 Formula The exact nutrient formula recommended by the National Eye Institute based on the AREDS2 Study.*† †For people with moderate to advanced age-related macular degeneration(AMD)
Join our FREE Program! With you in the fight against AMD (Age-related Macular Degeneration) Members Receive: PreserVision coupons valued up to $60 SightMatters AMD Starter Kit AMD information, expert advice, tips and tools Sign Up for Savings Get Helpful Answers A leading retina specialist answers frequently asked questions.
*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.
Text/HTML Expand All Collapse All References National Eye Institute website: http://www.nei.nih.gov/areds2/ Accessed October 2013. Age-Related Eye Disease Study 2 Research Group. Lutein + zeaxanthin and omega-3 fatty acids for age-related macular degeneration: the Age-Related Eye Disease Study 2 (AREDS2) randomized clinical trial. JAMA. 2013 May 15;309(19):2005-15. Age-Related Eye Disease Study Research Group. A randomized, placebo-controlled clinical trial of high-dose supplementation with Vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS Report No. 8. Arch Ophthalmol. 2001:119(10):1417-1436.
Expand All Collapse All References National Eye Institute website: http://www.nei.nih.gov/areds2/ Accessed October 2013. Age-Related Eye Disease Study 2 Research Group. Lutein + zeaxanthin and omega-3 fatty acids for age-related macular degeneration: the Age-Related Eye Disease Study 2 (AREDS2) randomized clinical trial. JAMA. 2013 May 15;309(19):2005-15. Age-Related Eye Disease Study Research Group. A randomized, placebo-controlled clinical trial of high-dose supplementation with Vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS Report No. 8. Arch Ophthalmol. 2001:119(10):1417-1436.